{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-046583","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.279255+00:00","generated_at":"2026-05-30T02:44:40.053395+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ocugen Q3 2024 cash $39M; extends runway into 1Q2026 on $65M in financings","bullets":["Cash and restricted cash $39.0M as of Sept 30, 2024, vs $39.5M at Dec 31, 2023.","Closed $30M debt and $35M equity financings in Q3, extending cash runway into 1Q2026.","Total operating expenses $14.4M (R&D $8.1M, G&A $6.3M) vs $16.1M in Q3 2023.","OCU400 Phase 3 liMeliGhT trial for RP on track to complete enrollment in 1H2025.","OCU410 Phase 2 recruiting; OCU410ST DSMB approved Phase 2; OCU200 IND cleared for Phase 1."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-046583","json":"https://secwatch.observer/filing/0001628280-24-046583.json","markdown":"https://secwatch.observer/filing/0001628280-24-046583.md","text":"https://secwatch.observer/filing/0001628280-24-046583.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024046583/0001628280-24-046583-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024046583/ocgn-20241108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:44:40.053395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}